Tashvin Paul

Tashvin Paul

Auto-generated profile, based on publicly available information

Tashvin Paul

Avalon University School of Medicine, Willemstad, Curaçao

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
TPTashvin Paul
Tashvin Paul
TPTanya Paul
Tanya Paul
SKShailendra Katwal
Shailendra Katwal
PAParinita Aroori
Parinita Aroori
PDPrachi Dawer
Prachi Dawer
TYTularam Yadav
Tularam Yadav
Industries widely utilize benzene in the production of plastics, resins, and fibers. It is also present in cigarette smoke, gasoline, and motor vehicle exhaust. Unfortunately the widespread use is also associated with a significant risk of malignancies. Leukemias, lymphomas, and lung cancers are among the malignancies commonly linked to benzene exposure. Studies have described various pathophysiological mechanisms involving interactions between the immune system, stem cells, and oxidative stress. These changes are linked to chromosomal abnormalities and the development of a mutator phenotype. In addition to cancers, benzene is associated with the acceleration of lifestyle diseases such as cardiovascular disease and metabolic syndrome. Other carcinogens include ultraviolet radiation, processed meat, and various air pollutants. Authorities have implemented various regulations have been established to limit exposure to such hazardous chemicals. Additionally, recommendations have been issued regarding actions to take in the event of acute benzene exposure. By raising awareness and enforcing stringent laws, the incidence of benzene-associated cancers can decline.

29 July 2026 in Turkish Journal of Internal Medicine
Verified
Journal Article
Open access
ASArihant Senthil
Arihant Senthil
TPTashvin Paul
Tashvin Paul
KSKaranbir Singh
Karanbir Singh
MKMahima Kamble
Mahima Kamble
JHJinpyo Hong
Jinpyo Hong
RJRohit Jain
Rohit Jain
Objective: Hemophilia, a genetic bleeding disorder caused by deficiencies in clotting factors VIII, IX, or XI, has transitioned from a fatal disease to a chronic but manageable condition. Traditional management with plasma-derived and recombinant factor replacement improved survival and reduced bleeding but remains limited by frequent infusions, inhibitor development, and incomplete protection against joint damage.Methods: This narrative review was based on a literature search of PubMed/MEDLINE and Google Scholar, focusing on recent clinical studies, guidelines, and landmark publications on hemophilia therapies.Results: Recent therapeutic advances have transformed hemophilia management by reducing treatment burden, improving bleed prevention, and enhancing patient quality of life. Extended half-life factor concentrates have decreased infusion frequency, while non-factor therapies have expanded effective prophylaxis for patients with and without inhibitors through convenient subcutaneous administration. Gene therapy has demonstrated sustained endogenous factor expression with substantial reductions in bleeding episodes, offering the potential for long-term disease modification. Despite these advances, challenges related to treatment durability, immune responses, patient eligibility, accessibility, and cost continue to limit widespread implementation.Conclusion: This narrative review outlines the evolution of hemophilia therapy from replacement strategies to innovative mechanism-based approaches, emphasizing clinical outcomes, emerging challenges, and the imperative to translate advances into equitable, sustainable care.